The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene label mismatch: BRCA2 vs undefined
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_000059.4(BRCA2):c.8188G>C (p.Ala2730Pro)

CA025499

126168 (ClinVar)

Gene: BRCA2 (HGNC:675)
Condition: BRCA2-related cancer predisposition (MONDO:0700269)
Inheritance Mode: Autosomal dominant inheritance
UUID: 3f547b0b-79ac-4767-a585-99c5cce3ad32
Approved on: 2026-01-05
Published on: 2026-01-05

HGVS expressions

NM_000059.4(BRCA2):c.8188G>C (p.Ala2730Pro)
NM_000059.4:c.8188G>C
NC_000013.11:g.32363390G>C
CM000675.2:g.32363390G>C
NC_000013.10:g.32937527G>C
CM000675.1:g.32937527G>C
NC_000013.9:g.31835527G>C
NG_012772.3:g.52911G>C
ENST00000470094.2:c.8188G>C
ENST00000528762.2:c.8188G>C
ENST00000530893.7:c.7819G>C
ENST00000665585.2:c.8188G>C
ENST00000666593.2:c.8188G>C
ENST00000700202.2:c.8188G>C
ENST00000700202.1:c.655G>C
ENST00000380152.8:c.8188G>C
ENST00000544455.6:c.8188G>C
ENST00000614259.2:c.8196G>C
ENST00000665585.1:c.753G>C
ENST00000680887.1:c.8188G>C
ENST00000380152.7:c.8188G>C
ENST00000544455.5:c.8188G>C
NM_000059.3:c.8188G>C
More

Likely Pathogenic

Met criteria codes 4
PS3 BS1_Supporting PP3 PP4_Moderate
Not Met criteria codes 2
BA1 PM2

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for BRCA2 Version 1.1.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
ENIGMA BRCA1 and BRCA2 VCEP
The c.8188G>C variant in BRCA2 is a missense variant predicted to cause substitution of Alanine by Proline at amino acid 2730 (p.(Ala2730Pro)). The highest non-founder population filter allele frequency in gnomAD v4.1 (read depth ≥20) is 0.00002550 in the African/African American population which is within the ENIGMA BRCA1/2 VCEP threshold (>0.00002 to ≤ 0.0001) for BS1_Supporting (BS1_Supporting met). Reported by three calibrated studies to exhibit protein function similar to pathogenic control variants (PMIDs:38417439, 39779857, 39779848) (PS3 met). This BRCA2 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.38, above the recommended threshold of 0.30 for prediction of impact on BRCA2 function via protein change. A SpliceAI score of 0 predicts no impact on splicing (score threshold <0.10) (PP3 met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 18.13 (based on Family History LR=18.13), within the thresholds for moderate evidence towards pathogenicity (LR >4.3 & ≤18.7) (PP4_Moderate met; PMID: 31853058). In summary, this variant meets the criteria to be classified as a Likely pathogenic variant for BRCA2-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (BS1_Supporting, PS3, PP3, PP4_Moderate).
Met criteria codes
PS3
Reported by three calibrated studies to exhibit protein function similar to pathogenic control variants (PMIDs:38417439, 39779857, 39779848) (PS3 met).
BS1_Supporting
The highest non-founder population filter allele frequency in gnomAD v4.1 (read depth ≥20) is 0.00002550 in the African/African American population which is within the ENIGMA BRCA1/2 VCEP threshold (>0.00002 to ≤ 0.0001) for BS1_Supporting (BS1_Supporting met).
PP3
This BRCA2 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.38, above the recommended threshold of 0.30 for prediction of impact on BRCA2 function via protein change. A SpliceAI score of 0 predicts no impact on splicing (score threshold <0.10) (PP3 met).
PP4_Moderate
Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 18.13 (based on Family History LR=18.13), within the thresholds for moderate evidence towards pathogenicity (LR >4.3 & ≤18.7) (PP4_Moderate met; PMID: 31853058).
Not Met criteria codes
BA1
The highest non-founder population filter allele frequency in gnomAD v4.1 (read depth ≥20) is 0.00002550 in the African/African American population which is within the ENIGMA BRCA1/2 VCEP threshold (>0.00002 to ≤ 0.0001) for BS1_Supporting (BS1_Supporting met).
PM2
The highest non-founder population filter allele frequency in gnomAD v4.1 (read depth ≥20) is 0.00002550 in the African/African American population which is within the ENIGMA BRCA1/2 VCEP threshold (>0.00002 to ≤ 0.0001) for BS1_Supporting (BS1_Supporting met).
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
ClinGen Terms of Use.
¤ Powered by BCM's Genboree.